What is the target of tucatinib/tucatinib? How does it work?

Tucatinib/Tucatinib is a kinase inhibitor whose main target is HER2 ( human epidermal growth factor receptor 2), for the treatment of certain types of unresectable/metastatic HER-2 positive breast cancer. Tucatinib was launched in the United States in 2020 in 4 months and in 2020 It will be launched in Australia in March, and it will be approved for medical use in the European Union in February 2021.

Mutations in the HER-2 gene are seen in certain types of breast cancer. Tucatinib inhibits the tyrosine kinase of the HER-2 gene. Mutations in the tyrosine kinase 1HER-2 gene lead to a cascade of increased cell signaling and proliferation, leading to malignancy. In vitro study results show that tucatinib inhibits the phosphorylation of HER-2 and HER-3, leading to downstream changes in MAPK and AKT signaling and cell proliferation. Cells expressing HER-2 have anti-tumor activity. In vivo, tucatinib may inhibit HER-2-expressing tumors by the same mechanism. By inhibiting tyrosine kinases, tucatinib exerts antitumor activity and reduces the size of HER-2positive breast cancer tumors. In clinical trials, tucatinib and trastuzumab showed enhanced activity in vitro and in vivo compared with either agent administered alone. There is a generic version of this drug in Bangladesh. The retail price of Everest Pharmaceuticals in Bangladesh is about 150mg30 tablets6000 yuan. The retail price of Ziska Pharmaceuticals in Bangladesh is around 4,500 yuan for 150 mg 30 tablets. If you want to get more high-quality information, you can contact Yaode, and Yaode will do its best to help you learn more about high-quality overseas drugs.